ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ORAMED PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$4.06−0.01 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $172.56M
- P/E (TTM)
- 1.0
- Dividend yield
- 6.16%
Oramed Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $168.89M | $166.30M |
| Enterprise Value | $152.79M | $88.19M |
| PE Ratio | 0.98 | 20.44 |
Income (trailing twelve months)
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$14.52M | -$21.40M |
| Pretax Income | $220.28M | -$14.34M |
| Net Income | $174.87M | -$22.46M |
| EBITDA | -$14.52M | -$16.91M |
| EPS (Diluted) | $4.13 | -$0.83 |
Returns
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 113.2% | -53.2% |
| Return on Assets (ROA) | 65.8% | -40.9% |
| Return on Invested Capital (ROIC) | -8.42% | -32.4% |
| Return on Capital Employed (ROCE) | -4.05% | -38.1% |
Growth
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -9.55% | 2.25% |
| Revenue Growth (5Y CAGR) | -5.85% | 6.48% |
| EPS Growth (3Y CAGR) | 24.4% | -0.17% |
| EPS Growth (5Y CAGR) | 12.8% | 3.77% |
Balance sheet
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $16.09M | $61.43M |
| Net Cash (Debt) | $16.09M | $15.35M |
| Net Cash Per Share | $0.39 | $0.66 |
| Working Capital | $42.68M | $76.81M |
Financial position
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 4.98 | 3.34 |
| Quick Ratio | 1.50 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.21M | -$12.35M |
| Capital Expenditures | -$9.00K | -$1.08M |
| Free Cash Flow | -$5.22M | -$20.22M |
| FCF Per Share | -$0.13 | -$0.42 |
Efficiency
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | $13.45M | -$703.34K |
| Employee Count | 13 | 74 |
Dividends and yields
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 103.5% | -23.3% |
| FCF Yield | -3.09% | -8.72% |
| Dividend Yield | 6.16% | 1.82% |
| Shareholder Yield | 6.16% | 0.00% |
| Dividend Per Share | $0.25 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 41,597,400 | 58,127,000 |
| Shares Change (YoY) | 1.52% | 10.9% |
| Shares Change (QoQ) | 0.95% | 0.54% |
| Float | 31,587,300 | 49,136,700 |
| Shares Held by Insiders | 24.1% | 11.6% |
| Shares Held by Institutions | 40.3% | 59.4% |
Taxes
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $45.41M | $79.87K |
| Effective Tax Rate | 20.6% | 20.6% |
Scores
| Measure | Oramed Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 1.92 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Oramed Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.